WATCH LIVE
timothy sykes logo
CELZ Stock Whipsaws As FDA Trial Expansion And AI Push Grab Attention Thumbnail
G Google News

CELZ Stock Whipsaws As FDA Trial Expansion And AI Push Grab Attention

TIM SYKES•UPDATED JUN. 30, 2026, 9:18 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Creative Medical Technology Holdings Inc. rallies after regenerative medicine advances, as stocks have been trading up by 183.91 percent.

Key Takeaways

  • FDA cleared Creative Medical Technology to expand its ADAPT Phase 2 trial of CELZ-201 for chronic lower back pain, adding a 15-patient, lower-opioid cohort that is already over 85% enrolled.
  • Positive 180-day safety and efficacy data from the ADAPT trial are helping Creative Medical Technology prepare for potential Phase 3 talks on CELZ-201 in chronic lower back pain.
  • Shares of CELZ slipped about 1% after the FDA expansion news, hinting that traders want harder data before bidding higher.
  • Project PHOENIX / CELZ-Biodefense has moved into a nationwide, AI-driven virtual data collection phase focused on at least 1,000 toxic-exposed U.S. veterans.
  • Creative Medical Technology says it can run this Project PHOENIX phase and build its CELZ-Biodefense Toxic Exposure Atlas using existing infrastructure without raising new capital.

Candlestick Chart

Live Update At 09:18:19 EDT: On Tuesday, June 30, 2026 Creative Medical Technology Holdings Inc. stock [NASDAQ: CELZ] is trending up by 183.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELZ is trading like a classic high-risk biotech: big stories, tiny revenue, heavy losses, and sharp price swings. Recent quarterly revenue was just $6,000, while net loss came in around $1.4M. That’s a steep burn, confirmed by operating cash flow of about -$1.32M for the quarter. For traders, this screams “story stock,” not value play.

On the balance sheet, CELZ shows roughly $5.7M in cash against only about $0.3M in liabilities. The current ratio near 19.7 tells you Creative Medical Technology is not drowning in debt right now. With total assets of about $6.4M and equity around $6.1M, leverage is light, but returns are deeply negative, with return on equity below -70%. Management is spending aggressively to build CELZ-201 and the CELZ-Biodefense platform.

More Breaking News

The chart confirms the rollercoaster. CELZ hovered above $2.00 for many days, then slammed down to about $0.81 on 2026/06/29. Intraday data shows a premarket spike from under $1.00 to the mid-$2s in less than an hour, then heavy whipping around. That kind of volatility attracts day traders, but it also punishes anyone who overstays. In this setup, CELZ rewards discipline and punishes hesitation.

Why Traders Are Watching CELZ Momentum

Traders are zeroed in on CELZ because the company just secured FDA clearance to expand its ADAPT Phase 2 trial of CELZ-201 (also called Olastrocel) for chronic lower back pain. That is not just a paperwork tweak. It lets Creative Medical Technology add a new cohort of opioid-using patients on lower doses, with enrollment already more than 85% done. Regulators do not greenlight expansions like this unless the trial is at least behaving as expected so far.

CELZ has also reported positive interim 180-day safety and efficacy data from this ADAPT study, and management is already talking about preparations for Phase 3 discussions. For a tiny company with only $6,000 in quarterly revenue, a late-stage pain asset is the entire ballgame. Chronic lower back pain is a huge market, and showing safety in patients still using opioids—with AI-based monitoring of their medications—gives CELZ-201 a clear angle that bigger pharma will watch.

Yet the market reaction was muted. CELZ slipped about 1% on the FDA expansion headline. That tells traders expectations were already elevated after earlier news, or that the market wants to see full Phase 2 data before rewarding the stock again. For the active trading crowd, this disconnect between improving fundamentals and soft price action creates opportunity—but only with strict risk rules.

At the same time, Creative Medical Technology is pushing Project PHOENIX / CELZ-Biodefense into a nationwide, AI-driven virtual study of at least 1,000 veterans exposed to burn pits and other toxic hazards. The goal is a CELZ-Biodefense Toxic Exposure Atlas—a massive, multi-omics dataset that could power future regenerative therapies. CELZ says it can run this phase with its current infrastructure, without raising more cash, which is critical in a tight biotech funding environment. Long term, that data asset could become a separate catalyst that makes CELZ more than a one-drug story.

Conclusion

CELZ sits at the center of a classic biotech tension: strong narrative versus brutal numbers. On one side, Creative Medical Technology’s CELZ-201 program is stepping closer to Phase 3, backed by FDA clearance to expand the ADAPT trial and encouraging 180-day data in chronic lower back pain. On the other, the company is burning over $1M per quarter on minimal revenue, with deep negative returns on capital. That gap between promise and present reality is exactly what drives the wild trading we see in CELZ.

Project PHOENIX and the CELZ-Biodefense Toxic Exposure Atlas add another layer. A nationwide, AI-powered dataset on toxic-exposed veterans, built without new fundraising, shows operational discipline and a longer-term vision. But traders need to remember that this is early-stage platform building, not an immediate revenue engine. The tape will likely react first to trial updates and financing headlines, then to any clear monetization path for the CELZ-Biodefense data.

For active traders, CELZ is a teaching chart. Big gaps, fast spikes, and sharp fades demand a real plan. As Tim Sykes likes to say, “The market doesn’t care about your potential, it rewards your discipline.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”. With Creative Medical Technology and CELZ, that means respecting the volatility, cutting losses quickly, and treating every catalyst—FDA moves, trial readouts, or Project PHOENIX milestones—as a trading setup, not a guarantee. This analysis is for educational and research purposes only, and each trader must decide how, or if, CELZ fits their own strategy.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”